Actively Recruiting
Observational Study of Switching from Ranibizumab or Aflibercept to Faricimab in Patients with Refractory or Dependent Exudative Age-Related Macular Degeneration
Led by Nantes University Hospital · Updated on 2025-01-16
100
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
Sponsors
N
Nantes University Hospital
Lead Sponsor
R
Rennes University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Age-related macular degeneration (AMD) is a condition that affects the retina, leading to vision problems. Treatments with anti-VEGF drugs like ranibizumab and aflibercept have improved outcomes for the exudative form of AMD. A newer drug called Faricimab, which targets VEGF-A and ANG2, has been authorized for use in France and may allow longer intervals between injections compared to previous treatments. This study focuses on patients with AMD who have already been treated with ranibizumab or aflibercept and aims to evaluate switching to Faricimab in real-life settings. Participants will switch from their current anti-VEGF treatment (ranibizumab or aflibercept) to Faricimab. The study will observe the effects of this switch, particularly looking at the length of time between injections over a six-month period after changing to Faricimab. The study is observational and retrospective, involving multiple centers. During the study, researchers will measure how the injection intervals change after switching treatments, comparing the number of weeks between injections before and after six months of Faricimab treatment. Participants will be monitored for up to one year to assess outcomes. The study will help understand the practical benefits and treatment patterns with Faricimab in patients previously treated with other anti-VEGF drugs.
CONDITIONS
Official Title
Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patient of legal age (≥18 years) with exudative AMD treated with IVT ranibizumab or aflibercept for more than 1 year
- Patient whose IVT injection interval is strictly less than 12 weeks
You will not qualify if you...
- Severe myopia (axial length > 26 mm or sphere < -6 dioptres)
- Presence of angioid striae
- Presence of moderate or more severe diabetic retinopathy
- History of diabetic macular edema
- History of uveitis
- Previous retinal vein occlusion (branch or central vein)
- History of pseudovitelliform macular dystrophy
- Patient under guardianship or trusteeship
- Pregnant or breast-feeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ducloyer
Nantes, France, 44000
Actively Recruiting
Research Team
J
Jean-Baptiste Ducloyer, M.D
A
Alexandra Poinas, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here